ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0747

Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis

Irene Carrión-Barberà1, Ryan D. Stultz2, David Cuthbertson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Paul Monach8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Kenneth Warrington12, Peter Merkel7 and Christian Lood13, 1Department of Rheumatology. Hospital del Mar, Barcelona, Spain, 2University of Washington, Division of Rheumatology, Seattle, WA, 3University of South Florida, Tampa, 4Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Moreland Hills, OH, 7University of Pennsylvania, Philadelphia, PA, 8VA Boston Healthcare System, Boston, MA, 9University of Colorado, Denver, CO, 10Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, ROCHESTER, MN, 13University of Washington, Division of Rheumatology, Seattle

Meeting: ACR Convergence 2025

Keywords: giant cell arteritis, immunology, macrophages, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage polarization induced by patient serum may uncover disease-specific immune signatures and therapeutic targets.

Methods: Purified monocytes from healthy donors were differentiated into macrophages (M0) using M-CSF and 10% fetal bovine serum for 4 days, followed by polarization toward M1 (IFNγ + LPS), M2a (IL-4 + IL-13), M2b (immune complexes + LPS), or M2c (IL-10 + dexamethasone) phenotypes. These in vitro-polarized macrophages served as the training dataset. Flow cytometry assessed CD40 (M1 marker), CD206 (M2a), HLA-DR (negative in M2b), and CD163 (M2c) expression. Macrophages exposed to serum from patients in remission with GCA (n=40), TAK (n=40), and healthy controls (HC, n=19) were analyzed (test samples). Data were extracted from FlowJo™ workspaces using CytoML and flowWorkspace in R and arcsinh-transformed. A K-Nearest Neighbors (KNN) classifier (k=10) trained on M0–M2c macrophages predicted phenotypes in test samples. Uniform Manifold Approximation and Projection (UMAP) was used for visualization, using 250 cells/sample for training and test samples, and all available cells for other analysis. Group-level differences were assessed using Fisher’s exact test, and per-sample differences with Mann–Whitney U tests.

Results: UMAP visualization revealed distinct clustering patterns among groups. Macrophages exposed to HC serum formed a relatively compact cluster, while those exposed to serum from patients with GCA and TAK showed greater dispersion, especially TAK, indicating broader phenotypic heterogeneity (Figure 1a-b). Spatial distribution of individual polarization markers is shown through UMAP overlays (Figure 1c-f).Quantitative analysis revealed that GCA samples retained the highest proportion of M0-like macrophages, followed by TAK, with HC showing the lowest. HC exhibited the highest proportions of M2a- and M2c-like macrophages, while TAK samples showed an increase in M2b-like macrophages. Despite tighter spatial clustering, HC macrophages polarized toward more varied phenotypes than the other groups (Figure 2). There were statistically significant differences among all groups, except for M1 between GCA and TAK. Although the proportion of M1 was negligible across all groups, HC showed a 6- and 4-fold increased prevalence compared to GCA and TAK, respectively.

Conclusion: Serum from patients with GCA and TAK induces distinct macrophage polarization profiles compared to HC. Serum in GCA maintains macrophages in an undifferentiated M0-like state, whereas serum in TAK promotes a modest M2b-skewed response associated with immune complex stimulation. In contrast, serum in HC predominantly favors regulatory and repair-associated macrophage phenotypes (M2a and M2c). These findings highlight macrophage phenotyping as a promising tool to uncover disease-specific immune dysregulation in large-vessel vasculitis.

Supporting image 1Figure 1: Uniform Manifold Approximation and Projection (UMAP) of training samples M0-M2c (a), test samples (b) and individual polarization markers (c-f).

Supporting image 2Figure 2: Percentage of each macrophage phenotype per group within all the cells of that group (a-c-e-g-i). Percentage of the median +/- interquartile range of each phenotype within each cell of the group (b-d-f-h-j). n.s. = non-significant; * = p-value < 0.05 – 0.01 ; ** = p-value < 0.01 – 0.001; *** = p-value < 0.001. GCA: giant cell arteritis; TAK: Takayasu’s arteritis; HC: healthy control.


Disclosures: I. Carrión-Barberà: AstraZeneca, 6, GlaxoSmithKlein(GSK), 2; R. Stultz: None; D. Cuthbertson: None; N. Khalidi: AbbVie/Abbott, 2, 5, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 5, GlaxoSmithKlein(GSK), 2, 6, Mallinckrodt, 2, NS Pharma, 5, Otsuka, 2, 6, Roche, 2, 6, Sanofi, 2, 5; C. Koening: Amgen, 1, Boehringer-Ingelheim, 1; C. Langford: AbbVie/Abbott, 12, Non-paid consultant, AstraZeneca, 5, 12, Non-paid consultant, Bristol-Myers Squibb(BMS), 5, 12, Non-paid consultant, GlaxoSmithKlein(GSK), 5, NS Pharma, 5; C. McAlear: None; P. Monach: Boehringer-Ingelheim, 2; L. Moreland: None; C. Pagnoux: amgen, 1, 2, 6, Astra zeneca, 1, 6, csl vifor, 1, 2, 6, gsk, 1, 2, 6, Novartis, 2, ns pharma, 1, otsuka, 1, 2, 5, 6, Pfizer, 2, 6; P. Seo: None; K. Warrington: Bristol-Myers Squibb(BMS), 5, Sanofi, 2; P. Merkel: AbbVie, 2, 5, Alpine, 2, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb (BMS), 2, 5, CSL Behring, 2, Eicos, 5, Electra, 5, GlaxoSmithKlein (GSK), 2, 5, iCell, 2, Interius, 2, Kinevant, 2, Kyverna, 2, 11, Lifordi, 11, Metagenomia, 2, Neutrolis, 2, 5, 11, Novartis, 2, NS Pharma, 2, Otsuka, 2, Q32, 2, 11, Quell, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, 11, Takeda, 2, 5, UpToDate, 9, Vistera, 2; C. Lood: Archon, 5, Boehringer-Ingelheim, 5, Citryll, 2, Gilead Sciences, 5, Neutrolis, 5, Pfizer, 5, Redd Pharma, 1, 2, 5, 11.

To cite this abstract in AMA style:

Carrión-Barberà I, Stultz R, Cuthbertson D, Khalidi N, Koening C, Langford C, McAlear C, Monach P, Moreland L, Pagnoux C, Seo P, Warrington K, Merkel P, Lood C. Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/patterns-of-macrophage-polarization-induced-by-serum-from-patients-with-giant-cell-arteritis-and-takayasus-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-macrophage-polarization-induced-by-serum-from-patients-with-giant-cell-arteritis-and-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology